
|Videos|March 14, 2019
Highlighting CAR T Cell Options for Relapsed/Refractory DLBCL
Author(s)David Miklos, MD
David Miklos, MD, discusses his advice for community oncologists treating patients with diffuse large B-cell lymphoma.
Advertisement
David Miklos, MD, associate professor of medicine at Stanford University, discusses his advice for community oncologists treating patients with diffuse large B-cell lymphoma (DLBCL).
Miklos says it is important to know that chimeric antigen receptor (CAR) T cells are effective and available for patients with relapsed/refractory DLBCL.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
2
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
3
How Inherited BRCA Mutations Shape Breast Cancer's Genomic Behavior and Point Toward a New Treatment Paradigm
4
Community Clinical Trials and the Lung Cancer Pipeline
5




























